Anbenitamab, CAS 2367012-88-0

Product Description: Anbenitamab (KN-026) is a bispecific antibody simultaneously targeting the extracellular domains II and IV of the human HER2. Anbenitamab blocks both ligand-dependent and ligand-independent HER2 signaling pathway. The IgG1 Fc fragment of Anbenitamab binds FcRγIIIa mediates potent antibody dependent cell-mediated cytotoxicity (ADCC) and inhibits tumor cell proliferation. Anbenitamab has the potential for HER2-positive metastatic breast cancer (MBC) research[1][2].

Applications: Cancer-Kinase/protease

Formula: N/A

References: [1]Dongmei Ji, et al. Abstract 3022: Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody. Cancer Res (2020) 80 (16_Supplement): 3022./[2]Jian Zhang, et al. First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study. Clin Cancer Res. 2022 Feb 15;28(4):618-628.

CAS Number: 2367012-88-0

Molecular Weight: N/A

Compound Purity: 99.22

Research Area: Cancer

Solubility: H2O

Target: EGFR

• SKU: MEXHY-P99437-5
• Manufacturer: MedChemExpress
• Manufacturer SKU: HY-P99437-5
• Green Labware: No
• Package Unit: 5 mg
• Quantity Unit: STK